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Abstract: Mesenchymal stromal cells (MSCs) participate in repair of damaged tissues, possess the potential to serve as a 
useful tool in the drug discovery field and exert immunosuppressive effects as demonstrated by their ability to modulate 
the immune response. Herein, the roles played by MSC differentiation and/or production of trophic factors involved in tis-
sue repair are discussed. MSCs offer the opportunity to probe targets that conventional or differentiated cell lines do not 
express; thus providing a more refined system that allows identification of novel therapeutics. However, there are difficul-
ties associated with drug discovery assays to which MSCs are not exempt. The immunosuppressive potential of MSCs has 
already been utilised in clinical trials where MSCs have been used to treat patients with graft- versus- host disease 
(GvHD) and autoimmune diseases. Another possible therapeutic application of MSCs lies in the field of transplantation 
tolerance. Although the capacity of MSCs to modulate immune responses has received much attention, the role of MSCs 
in transplantation tolerance is as yet unclear. In this review, we discuss the evidence for MSC induction of a state of toler-
ance in the transplantation setting. 
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TISSUE REPAIR AND REGENERATION  
 In evolutionary terms, the appearance of multicellular 
organisms with specialised tissues and organs created a pro-
found challenge; the need to regenerate or restore damaged 
tissue. Tissue regeneration is the solution to this problem and 
is seen most dramatically in amphibians [1,2]. Here physio-
logical damage can induce a regenerative process that re-
stores both organ architecture and function. The fields of 
regenerative medicine and human tissue engineering seek to 
harness the mammalian counterparts of such processes for 
therapeutic use in humans. In mammalian systems studied to 
date, such processes rely on a complex interaction of non-
differentiated cells and trophic factors at the site of damage 
[3,4]. The precise nature of such complex interactions varies 
by disease/injury, target organ, species, age and other paral-
lel reparative processes. These processes may involve de-
differentiation of damaged tissue, trans-differentiation of 
progenitor cells, cell fusion, or differentiation of precursor 
stem cells [3]. As tissue resident and bone marrow derived 
stem and progenitor cells can contribute to regeneration, 
cells such as bone marrow derived mesenchymal stem cells 
(MSCs) have become a major feature of regenerative medi-
cine, and the basis of a rapidly growing industrial sector 
based on cell therapy [5,6]. 
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MSC History, Source and Characteristics 
 The term “mesenchymal stem cell” was coined by Caplan 
in 1991 [7,8] referring to the cells characterised by Frieden-
stein as bone marrow derived, plastic adherent cells with tri-
lineage differential potential [9,10]. It is perhaps worth recol-
lecting the differences between stem cells and committed 
progenitor cells. Stem cells have extended capability for self 
renewal, are telomerase positive and so not constrained by 
the Hayflick limit and can form all the cell types associated 
with the source germ layer lineage (whether ecto-, meso or 
endo-dermal). In contrast, progenitor cells have a finite 
lifespan confined by Hayflick’s limit (often <70 cell 
doublings) and in general more limited capacities for differ-
entiation (from unipotency to multipotency) [2]. Given this 
distinction, MSCs are probably more accurately described as 
multipotent mesenchymal stromal cells, progenitor cells 
closely related to the more plastic multipotent adult progeni-
tor cells (MAPCs) [11,12], as well as “marrow isolated adult 
multilineage inducible cells” (MIAMI cells) [13,14] and 
multipotent adult stem cells (MASCs) [15]. For the remain-
der of this review we will consider only MSCs. These cells 
can be isolated not only from bone marrow but also the der-
mis, dental pulp, lung, thymus, trabecular bone, and readily 
from adipose tissue and umbilical Wharton’s jelly [5,16-19].  
 Although much progress has been made, the field is 
hampered by the absence of specific, unique, identifying 
markers of MSCs and thus the International Society for Cell 
Therapy (ISCT) definition of MSCs has become an impor-
tant consensus point –this defines multipotent MSCs as plas-
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tic-adherent cells (under standard culture conditions) that 
express CD73, CD90 and CD105 but not the hematopoietic 
markers CD11a, CD19, CD34, CD45, or HLA-DR [20,21]. 
In addition to qualify as MSCs, isolated cells should demon-
strate the capacity to differentiate into osteocytes, adipo-
cytes, and chondrocytes in vitro when suitably stimulated 
[20,21]. It is important that researchers in drug discovery or 
research programs adhere to rigorous quality control regard-
ing MSCs, as populations can lose multipotency with pas-
sage [22,23]. Even so, it is likely that the ISCT definition 
allows groups to work with heterogenous populations that 
may include mixtures of genuine stem cells with other cells 
that are more likely committed progenitors, perhaps account-
ing for variability in some published data. More seriously, 
groups which fail to repeatedly monitor for hematopoietic 
contamination may be generating data of little value. While 
MSCs from different sources share differentiation capacity 
(adipocytes, osteoblasts and chrondrocytes) as well as phe-
notypic markers [24], more rigorous functional assays have 
identified clear differences in function. In particular, MSC 
derived from bone marrow and synovium were more effec-
tive in inducing repair in cartilage defect models than those 
from adipose or skeletal muscle [25]. Importantly, MSC de-
rived from dental pulp but not those derived from adipose or 
bone marrow generate dentin [26]. Whereas the capacity to 
differentiate into osteocytes, adipocytes, and chondrocytes 
are defining features of MSCs in vitro, more potent transdif-
ferentiation has been described. MSCs can be driven to dif-
ferentiate into myocytes, endothelium, cardiomyocytes, fi-
broblasts, neural cells, and possibly hepatocytes, epithelium 
or even insulin producing cells, depending on the stimuli 
[27-35]. This multipotentiality combined with the ease of 
culture and expansion, have led to MSCs becoming a lead 
therapeutic in the race for cell based regenerative therapies 
[6,36].  
Tissue Repair Through Direct Differentiation or Trans-
differentiation 
 MSCs have been used as regenerative cell therapies in 
numerous experimental models. For example, site directed 
administration of bone marrow MSCs to infarcted myocar-
dium resulted in the regeneration of the injured tissue [37-
40]. Furthermore mouse MSCs delivered into healthy adult 
myocardium resulted in the formation of new blood vessels 
in which donor cells were identifiable after transplantation 
[41,42]. Transplanted MSCs had differentiated in situ to sev-
eral cell types including cardiomyocytes, endothelial cells, 
pericytes and smooth muscle cells [41]. Using single cell 
marking this group also showed that cardiomyocytes were 
most likely to have been generated stochastically from a sin-
gle-cell-derived stem cell [42]. Similarly, in porcine models, 
MSCs have been shown to engraft into the host myocardium 
and differentiated to myogenic cells, reduce infarct size, and 
support other physiological improvements [43]. These ob-
servations are supported by studies suggesting that MSCs 
can engraft in vivo in bone, lungs, and liver [11,44-46], and 
that MSCs (in demineralised bone or other matrices) con-
tribute to bone growth and repair [47-49]. In rodent models 
of acute renal failure, male MSCs protected female recipients 
from induced pathology and male cells were not only local-
ized to tubular epithelium but also expressed characteristic 
lectins [50,51], these and other studies support local en-
graftment and differentiation into tubular epithelial cells. 
 MSCs can contribute to regeneration of ectodermal, 
mesodermal and endodermal tissues (reviewed in [52]), 
however these effects might be attributable to mechanisms 
other than differentiation. Indeed, the evidence for true MSC 
engraftment and direct reconstitution by MSC differentiation 
in vivo is currently not extensive despite the vast literature on 
these cells. Even in myocardial infarction models, both the 
level of engraftment and the number of MSC derived car-
diomyocytes seems to be too low to fully explain the thera-
peutic benefit, and likewise the beneficial effects of MSCs in 
acute ischemic renal disease models appears to be through 
differentiation-independent mechanisms [53-57].  
Tissue Repair Mediated by Trophic Factors  
 A conceptual advance in this debate came when it was 
proposed that much of the therapeutic benefit of MSCs was 
associated with the release of soluble factors that acted in a 
paracrine manner to promote repair [58,59]. Thus MSCs 
might be considered as trophic agents, which guide or “nour-
ish” the process of tissue repair rather than, or in addition to, 
direct differentiation and regeneration. Of course if MSCs 
are heterogeneous mixed populations, it is possible that tro-
phic action and differentiation are not mutually exclusive, or 
that different trophic effects may be performed by different 
sub-populations. The term “trophic effect” encompasses 
many functional characteristics of MSCs such as immuno-
modulation (see below) as well as anti-apopototic, cytopro-
tective effects and the promotion of angiogenesis [58]. The 
latter may be an important component of repair as it is 
known that vascular stability contributes to healing and that 
pericytes (mural cells) contribute to this [60]. Interestingly, 
MSCs express some pericyte markers and it has been pro-
posed that tissue resident MSCs may be derived from peri-
vascular precursors [16,47,61,62]. MSCs can also express 
VEGF [63] and therefore may be intimately involved in 
neovascularisation of wounds and suggesting this to be a key 
trophic contribution to regeneration. 
Effect of Licensing on MSC Potency 
 There is still a great deal to be discovered about the re-
generative process and the role of MSCs. Indeed much may 
still be learned from comparative systems in amphibians and 
other animals [1,2,4]. These and other studies have shown 
that regeneration requires tissue resident stem cells of differ-
ent potency and type supported by complex trophic factors at 
the site of damage. A process that is more subtle and broad 
than current models of MSC regeneration. Perhaps most in-
teresting is the demonstration by Lucas et al that the inflam-
matory process (linked to tissue damage) characterised by 
neutrophil and macrophage influx, was essential to regenera-
tion (reviewed in [1,2]). These studies indicated that a com-
plex mixture of progenitor cells (including fibrogenic and 
myofibrogenic progenitors, lineage committed stem cells and 
uncommitted pluripotent stem cells) were involved in the 
process. Inflammation was important for debridement and 
reserve/stem cell activation [1,2]. This is strikingly similar to 
the concept of “licensing” that has been proposed for mouse 
and human MSCs. Licensing suggests that MSCs are acti-
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vated and enhanced by inflammatory signals such as IFN-? 
at the site of repair and that such licensing enhances the re-
generative process [64]. This is supported by data from nu-
merous groups showing that inflammatory mediators gener-
ally do not break the immunosuppressive nature of MSCs 
but rather enhance it [65-69]. The implication being that fu-
ture cell therapy may benefit from pre-stimulation of MSCs.  
 The trophic influence of MSCs is likely to extend to 
other aspects of the repair process as well. For example, 
MSCs have a profound suppressive influence on fibrosis in 
vivo [70,71]. This may well be linked to the observation that 
human and mouse MSCs express the anti-fibrotic factor 
HGF and this is also upregulated by IFN-? prestimula-
tion/licensing [55,64,68,72]. Clearly MSCs play a complex 
role in tissue repair and these roles are achieved via multiple 
mechanisms. Overall regeneration and engraftment probably 
play a much smaller part than previously anticipated in the 
regenerative processes mediated by MSCs. Indeed features 
such as the anti-fibrotic effect and the powerful immune 
modulation that can be achieved by MSCs suggest that cell 
therapies using these cells may find most success against 
targets such as the chronic autoimmune diseases. However, it 
is important to note that MSC therapy is not a panacea. In 
particular the influence of MSCs on fibrosis will require fur-
ther study as MSCs can also express pro-fibrotic factors or 
promote fibrogenesis indirectly through differentiation into 
myofibroblasts [73]. Moreover MSC associated immune 
suppression can provide increased risk of infection in pa-
tients as has been documented in GvHD trials [74]. 
DRUG DISCOVERY 
 Current drug discovery programs rely on early stage, 
high throughput, hit identification protocols based on in vitro 
models. Indeed cell based in vitro systems contribute to hit 
identification, target validation, lead selection, as well as 
informing protocols around ADME-Tox. The disappointing 
late stage attrition of leads suggests that more refined ap-
proaches are now required [75]. Most current drug discovery 
systems are based on established transformed cell lines or 
specific primary cultures. Such lines have proved useful in 
addressing questions of pharmacological performance and 
safety, having the great advantage of near limitless scalabil-
ity. However these cell systems are of abnormal genotype 
(neoplastically transformed), are tissue lineage restricted, 
show abnormal physiological and growth characteristics and 
it is not surprising that stem cell approaches are being exam-
ined to improve these programs and to enhance the discovery 
process [75].  
Advantages of MSC based Drug Discovery Platform 
 Certainly, the greatest drug discovery potential lies in 
‘pluripotent’ human embryonic stem cells (hESCs) and in 
human somatic cells that have been reprogrammed into in-
duced pluripotent stem cells (iPSCs) with embryonic stem 
cell properties [75-78]. Drug discovery based on these cells 
is likely to become a main stream component of all pharma-
ceutical discovery strategies in the near future [77-80]. In-
deed MSC based approaches are already in use [81-83] and 
have major advantages over conventional non-candidate 
based hit identification programs. MSCs are not transformed, 
have less restricted lineage limitations, and display more 
relevant growth/ cell division characteristics [7,59]. In par-
ticular the expandability of umbilical cord MSCs derived 
from Wharton’s jelly make these cells good candidates for 
inclusion in high throughput screening (HTS) systems 
[18,52]. The current applications for MSCs are in compound 
screens, to probe structure-activity relationships, in the con-
version of hits to leads and in supporting or terminating the 
progression of lead molecules through the development 
process. This is particularly relevant to discovery pro-
grammes aimed at the development of treatments for osteo-
porosis, obesity, diabetes, metabolic disorders and joint dis-
ease, where MSCs provide an opportunity to deliver more 
targets and process appropriate information. In addition 
MSC screens may play an important role in the discovery of 
drugs targeting cancer stem cells or the tumour stroma 
[84,85]. 
 MSC based drug discovery protocols offer opportunities 
and advantages in two broad areas. The first area concerns 
targets that are currently difficult to assess. It is necessary to 
appreciate that certain drug targets may only be expressed at 
specific times during lineage development or in minority 
tumour tissue residents. MSCs offer an opportunity to probe 
such targets at specific differentiation stages whereas con-
ventional or differentiated cell lines do not without extensive 
manipulation. Thus MSCs offer a more refined and sophisti-
cated system that allows identification of small molecules 
acting at unique stages of the differentiation process, and/or 
validation of more subtle (but potentially more relevant) tar-
gets [79-80,86]. The second area concerns the exploitation of 
the immune modulatory aspects of MSC biology for drug 
discovery, an area ripe for exploitation. The major opportu-
nities for drug discovery are associated with two inter-linked 
disease processes: inflammation and autoimmunity/ trans-
plantation. Inflammation is a key component of the patho-
logical processes of the major diseases requiring new thera-
pies, and targeting inflammation is a major feature of most 
drug discovery programmes. The potent anti-inflammatory 
potential of MSC discussed below, allows these cells to be 
combined with RNAi libraries in high throughput and high 
content screens, to identify anti-inflammatory candidates and 
particularly candidate combinations. The use of MSC in drug 
discovery for novel therapies supporting transplantation or 
targeting autoimmunity is nascent. However the very recent 
demonstration that regulatory/tolerogenic T cells are not only 
induced by MSC but that such cells are effective and neces-
sary at reducing immune mediated pathology in animal mod-
els is important [87]. This suggests that MSC may be a rich 
source of novel tolerogenic and suppressive factors of real 
value. In effect MSC might be profitably exploited to dis-
cover both candidate drugs and novel mechanisms to pro-
mote transplant tolerance or suppress autoimmune and hy-
persensitivity reactions. 
 The most likely approaches to develop novel screens will 
combine MSC with RNAi or antagonist libraries. The com-
bination of MSC based high throughput assays with RNAi 
libraries allows functional screening to be performed with a 
high level of complexity [88-90]. A process that offers a rich 
vein of potential novel hits and leads; however, the assump-
tions underlying RNAi use in these systems need to be con-
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sidered carefully. The uptake of siRNA, and the efficacy of 
silencing are likely to be quite variable in such systems. Fur-
thermore the induction of intrinsic cell processes (such as 
production of type 1 interferons) can confound interpreta-
tion. Nevertheless the combination of more informative 
MSC assay approaches, extensive silencing libraries, and 
high throughput assay handling offer a powerful drug dis-
covery tool [88-91]. 
 In addition to the MSC based assay system, the choice of 
readouts needs careful consideration. For differentiation 
based approaches, these may be relatively straightforward 
such as the measurement of alkaline phosphatase activity as 
an early marker of osteogenesis. However the efficient in-
duction of some pathways such as cartilage formation re-
quires MSCs to be cultured in cell pellets, embedded in gels 
or some other three dimensional matrix. These systems pro-
vide additional challenges and may require both large num-
bers of cells and novel quality control protocols. Neverthe-
less such approaches have found application in osteoarthritis 
research, where modulators of early chondrogenic differen-
tiation may be measured by the expression of SOX-9 in 
MSC pellet cultures [92]. Although not strictly drug discov-
ery, MSC differentiation along the adipogenic pathway [93-
94] might also be used to probe environmental features of 
pollutants, environmental screening or bio distribu-
tion/accumulation in fatty tissue in ADME studies [95]. 
MSC derived adipocytes can also be used to screen lipolytic 
agents, or to assess modifiers of lipid accumulation, support-
ing discovery of novel therapeutic interventions in obesity 
and diabetes [95]. The selection of readouts for immunologi-
cal indicators will also be very dependent on the disease in-
dication of interest. It is quite feasible that if inflammation is 
the target then MSC approaches can be adapted to the myr-
iad of systems in current use. However future discovery 
based on tolerance induction or suppressor activity by MSC 
(discussed below) may well require new high content and 
high throughput approaches perhaps based on second cell 
readouts (dendritic cell or regulatory T cell) or more likely 
reporter approaches (such as FOX P3 expression). 
Limitations of MSC based Drug Discovery Platform 
 The benefits of MSC based drug discovery are chal-
lenged by two major difficulties: assay reproducibility and 
robustness, both of which have limited the wider application 
of MSC based assays [96]. Bone marrow derived MSCs 
show both donor-to-donor and lot-to-lot variability in prolif-
eration and differentiation potential; features which cause 
considerable trepidation when designing a drug discovery 
strategy and this might be especially problematic for immu-
nological indications. Unfortunately the difficulties do not 
end there, as MSCs defined by the ISCT and isolated by 
most published protocols are a heterogeneous mixture of 
similar mesenchymal cells, possibly containing more potent 
and stem like populations, along with cells with reduced po-
tential, pre-committed to single or dual lineages. Further-
more heterogeneity in populations is compounded by other 
features of differentiation. For example, even in adipocyte 
promoting conditions, a considerable percentage (30 -40%) 
of cells in a bone marrow derived MSC culture remain undif-
ferentiated [97,98]. Whilst these variations in potential pro-
vide a system-based robustness to the repair response in vivo, 
in the context of drug discovery such heterogeneity of re-
sponse creates serious challenges. Another related difficulty 
is that differentiation of MSCs to some cells such as cardio-
myocytes can be relatively inefficient using current proto-
cols. Thus screening processes need to operate when only 
small numbers of the specialised cells (signal) are produced 
against a non-differentiated background (noise) [96]. 
New Readout Systems  
 It is fortunate that recent advances in automated imaging 
and data processing have allowed the development of multi-
parameter endpoint quantitation techniques and helped to 
overcome some of the difficulties outlined above. The most 
widespread approaches have been termed high content 
screening (HCS) but may also be known as cell based 
screening, phenotypic screening or visual screening [88-
90,99,100]. HCS has been used predominantly as a research 
tool in industrial and academic situations. A basic example 
of HCS application is the determination of the effect of a 
potential drug/chemical on aspects of stem cell differentia-
tion and involves the combination of live cell imaging with 
sophisticated image analysis [86]. This research platform 
offers the potential to conduct large scale cell based screens 
in a more physiologically relevant experimental format and 
allows robust assays to be developed in situations where 
differentiation involves only a subset of the population ex-
ploited. Essentially HCS involves 5 steps, assay optimisation 
for scale up; image acquisition; automated image analysis, 
data management, data analysis/hit output. 
 Although HCS optimisation can be time consuming and 
complex, once attained, robust, reproducible and informative 
outputs can be achieved and novel hits obtained [101-103]. 
Such approaches may seem expensive, but higher quality 
information obtained early in the discovery process may lead 
to reduced late stage attrition and higher quality leads, mak-
ing combined MSC based assays with HCS readouts a feasi-
ble platform for novel drug discovery programmes.  
MSC IMMUNE MODULATION 
 The development of MSCs as therapeutic agents has pro-
gressed rapidly over the past 5 years and their potential as 
modulators of the immune responses has ignited great inter-
est in the field. Currently clinical trials focusing on MSCs 
for treatment of GvHD and autoimmune diseases are under-
way. One of the areas likely to benefit from the therapeutic 
effects associated with MSC immune modulation is that of 
transplantation [104]. 
The Impact of MSCs on Transplantation Rejection 
 To date transplantation remains the most effective treat-
ment for patients with established organ failure. While sig-
nificant advances in the development of immunosuppressive 
drugs has allowed the successful clinical application of organ 
transplantation, there are problems associated with long term 
administration of non-specific immunosuppressive drugs 
including increased susceptibility to infection and induction 
of diabetes, de novo malignancy, cardiovascular complica-
tions and renal failure [105]. Consequently, there is a clear 
requirement for the development of more specific immuno-
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suppressive therapies that are non-toxic for utilisation in the 
organ transplantation setting.  
 A large body of data supports the idea that MSCs can 
very effectively modulate the immune response both in vitro 
and in vivo and may therefore serve as a potential source of 
immunosuppressive therapy [106]. Certainly, data from both 
pre-clinical models and clinical trials suggest that MSCs 
have the capacity to modulate the immune response in vivo. 
However is it not yet clear whether or not MSCs can induce 
a state of tolerance in the setting of clinical organ transplan-
tation, but the outlook is promising [104].  
Influence of MSC on the Innate Immune Response  
 The innate immune response provides the first line of 
defence against infection and encompasses both cellular and 
non-cellular components including complement activation 
and the involvement of evolutionarily conserved pathogen 
recognition receptors (PRRs). In addition, innate immunity is 
also triggered by danger signals. Although rejection of allo-
geneic grafts is known to be mediated primarily by T cell 
and antibody responses [107,108], a number of studies now 
suggest that the innate immune response plays a role in the 
immune response to solid organ transplantation (reviewed in 
[109]).  
 MSCs used as a cell therapy in any inflammatory setting 
including organ transplantation will encounter the innate 
immune response and therefore it is important that we under-
stand how MSCs will interact with these first line responses. 
Recently Tu et al have demonstrated that human MSCs in-
hibit complement activation through secretion of factor H 
(the primary complement inhibitor found in serum) [110]. 
Furthermore, MSCs have been demonstrated to be respon-
sive to the complement activation products C3a and C5a, 
leading to migration and activation of MSCs [111]. Clearly, 
the interactions between MSCs and the complement system 
require further study, but it seems likely that MSCs are not 
only protected from deletion by innate mechanisms but are 
also responsive to such mechanisms; which may be impor-
tant at sites of tissue injury or ischemia reperfusion injury 
associated with transplantation. 
 Toll like receptors (TLRs) are the best studied PRRs and 
play an important role in activating the innate immune re-
sponse and subsequent shaping of adaptive immunity [112]. 
TLRs are found on many hematopoietic cells including B, T, 
mast cells and dendritic cells (DCs) and expression is aug-
mented by inflammatory mediators and danger signals. 
MSCs may be exposed to TLR ligands when administered to 
patients undergoing organ transplantation or indeed in any 
other inflammatory conditions. MSCs have been reported to 
express an array of TLRs and it is now clear that TLR signal-
ling has an effect on MSC survival, differentiation, migration 
and immunosuppressive capacity. TLR3 and TLR4 stimula-
tion prevented the suppressive effect of MSCs on T cell pro-
liferation and this was dependent on the downregulation of 
the Notch ligand jagged 1 [113]. In contrast, Opitz et al 
demonstrated that TLR3 and TLR4 ligation enhanced MSC 
immunomodulation through the indirect induction of IDO1 
[65]. A number of studies also report that TLR engagement 
in MSCs leads to changes in cytokine production [114-116] 
and therefore may allow further enhancement of immune 
suppression mediated by MSCs under certain conditions. 
Additionally, data demonstrate that ligation of TLR3 and 
TLR4, enhances MSC proliferation and migration in vitro 
[116,117] and augments the efficacy of MSCs in vivo in a rat 
model of myocardial infarction [118]. In general it appears 
that TLR signalling does not significantly impact MSC im-
mune suppression or trophic effects, but the consequences of 
TLR engagement and signalling in MSCs remain to be fully 
elucidated and therefore the field would benefit from further 
research in this area. 
 Although, monocytes/macrophages do not play a direct 
role in alloantigen presentation and therefore allorecognition; 
they actively infiltrate the allograft and proliferate in situ 
[119], contributing to the production of proinflammatory 
cytokines, reactive oxygen and nitrogen species [120]. Akin 
to the capacity of DCs to respond to their local microenvi-
ronment and become stimulatory or tolerogenic, monocytes 
and monocyte derived cells are also responsive to local cues. 
The best example of this is the generation of alternatively 
activated macrophages. Recent in vitro and in vivo data pro-
vide evidence that MSCs “educate” macrophages through 
cell-contact dependent cross talk leading to the generation of 
macrophages with an altered cytokine profile typically se-
creting IL-10 [121,122]. Another important role for macro-
phages is the participation in wound healing [123], the secre-
tion of trophic factors by MSCs has been shown to recruit 
these cells in a mouse model of excisional wound healing 
[124]. Therefore it seems that while MSCs modulate macro-
phage cytokine profiles, they do not appear to interfere with 
intrinsic macrophage wound healing properties. 
 Unlike macrophages, neutrophils can mediate tissue 
damage directly through the production of cytotoxic granules 
and pro-inflammatory cytokines. It is recognised that neutro-
phils infiltrate organs within hours after transplantation in 
response to surgical trauma or ischemia/reperfusion. MSCs 
have been shown to indirectly modulate neutrophil migration 
in a mouse model of sepsis. Interestingly, MSC induced se-
cretion of IL-10 by tissue resident macrophages which sub-
sequently limited the extent of the neutrophil infiltrate [122]. 
Through in vitro experiments, the authors demonstrate that 
this process required complex interaction between MSCs and 
macrophages and involved LPS activation of TLR4 in 
MSCs, leading to MSC production of PGE-2 which was en-
hanced by TNF-? – TNF receptor 1 engagement on MSCs 
[122]. The capacity for MSCs to directly or indirectly at-
tenuate the infiltration of neutrophils could potentially play 
an important part in MSC immune modulation of graft rejec-
tion and impact positively on the overall goal of the preven-
tion of graft damage in the transplantation setting. 
 Natural killer (NK) cells can significantly impact the 
outcome of solid organ transplantation. NK cells are cyto-
toxic to major histocompatibility complex (MHC) class I 
mismatched allogeneic cells and target these cells for de-
struction through contact mediated release of perforin, gran-
zyme and Fas ligand [125]. In addition, NK cells mediate 
their effector function through production of the pro-
inflammatory cytokines IFN-? and TNF-?. Early in vitro 
observations suggested that MSCs were not a target for lysis 
by freshly isolated NK cells and inhibited NK cell produc-
tion of IFN-? [126,127]. However, although more recent 
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findings corroborate MSC suppressive effects on NK cell 
cytokine production, proliferation and effector function 
[128], there is some evidence demonstrating that MSCs can 
be lysed by activated NK cells [128-130]. Overall, the data 
discussed herein emphasise the complexity of interaction 
between MSCs and the innate immune system and highlights 
the potential for exploiting these effects in the setting of or-
gan transplantation.  
Influence of MSCs on DCs 
 DCs are the primary antigen presenting cells which play 
a critical role in the activation of the adaptive immune re-
sponse; specifically the initiation of antigen specific T cell 
responses. Following organ transplantation, both donor and 
recipient derived DCs have the capacity to present alloanti-
gen to recipient T cells through the direct and indirect path-
ways of allorecognition respectively [109,131].  
 As DCs play such an important role in allograft rejection; 
much attention has focused on the effect that MSCs have on 
DC development and function. Notably, a number of studies 
support the idea that MSCs inhibit or interfere with DC dif-
ferentiation from precursor frequencies [132-135]. Impor-
tantly this effect is reversible and can be mediated by the 
MSC derived soluble factors IL-6 and PGE-2 [133]. MSCs 
may encounter DCs at different stages of development and 
under varying microenvironments and the specific conditions 
encountered will likely influence the effect that MSCs have 
on DCs. For example MSCs have differential effects on the 
generation of conventional DCs and plasmacytoid DCs [136].  
 Given the immune suppressive effects of MSCs, it seems 
likely that MSCs could orchestrate the induction of DCs with 
a regulatory or tolerogenic phenotype. To this end many 
studies have repeatedly shown that MSCs indeed induce a 
tolerogenic-like DC population through down modulation of 
MHC class II as well as the co-stimulatory molecules CD40, 
CD80 and CD86 [133,137-139]. This tolerogenic DC pheno-
type induced by MSCs was stable as restimulation with LPS 
did not reverse the effect. An outcome associated with MSC 
induction of tolerogenic DCs was a change in cytokine pro-
duction involving a switch from pro-inflammatory cytokines 
(IL-12, TNF-?) to the anti-inflammatory cytokine (IL-10) 
[126,134,140]. Notably, these MSC induced tolerogenic DCs 
display regulatory functions in their capacity to suppress the 
proliferation of rapidly expanding T cells [139], and to alter 
the ratio of T cell subsets and the frequency of regulatory T 
cells (Tregs) [137-141]. 
Interactions between MSCs and the Adaptive Immune 
Response 
 While T cell mediated immunity is central in allogeneic 
rejection mechanisms, humoral or antibody mediated im-
mune responses are also involved [107-108]. Since the early 
reports outlining the capacity of MSCs to inhibit T cell pro-
liferation in vitro, the field has progressed rapidly and we 
now have a greater understanding of how MSCs mediate 
their effects. A large body of data convincingly demonstrate 
that MSCs inhibit both alloantigen and mitogen driven T cell 
proliferation [64,142,143], but recent evidence suggests that 
MSCs have little effect on virally-driven proliferation [144]. 
Importantly, MSC capacity to modulate T cell responses is 
thought to be dependent on the inflammatory microenviron-
ment present at the time of interaction between these two cell 
types [66,145]. Indeed a mechanistic study carried out by 
Ren and colleagues demonstrated a requirement for IFN-?, 
TNF-? and/or IL-1? in the activation of MSC immune sup-
pressive function [145]. 
 Differentiation of naive helper T cells to specific subsets 
has also been shown to be altered in the presence of MSCs; 
skewing towards Tregs and preferential suppression of Th1, 
Th2 or Th17 depending on the system in question [122, 
146,147]. Support for this scenario has been provided in in 
vivo models of transplantation and autoimmune diseases 
where MSCs accommodate the augmentation of T cell sub-
sets in favour of a regulatory environment [141,147-149], 
and from preclinical models of MSC cell therapy where de-
pletion of CD4+CD25+ FOXP3+ Treg ablated the protective 
effect of MSC [87].  
 Tregs certainly have the potential to induce tolerance in 
organ transplantation and it is well established that Tregs can 
control alloreactive T cell responses [150-152]. Mechanisti-
cally, the induction of Tregs by MSCs is an important feature 
of MSC mediated immunosuppression particularly in the 
setting of transplantation; where the induction of tolerance to 
graft associated antigens is the paramount goal. To this end, 
MSC induced Tregs have been shown to be donor-specific in 
a mouse model of cardiac allograft rejection [148]. The 
mechanisms involved in MSC induction of Tregs have been 
investigated by a number of groups. While cell contact, 
PGE2 and TGF-? have been identified as key mediators 
[153], MSC secretion of HLA-G in an -IL-10 and -cell con-
tact dependent manner or in combination with LIF have also 
been identified to contribute to the expansion of Tregs in 
vitro in different systems [154,155].  
 Although the majority of studies focus on the effects of 
MSCs on CD4
+
 T cells, a small number of reports have 
demonstrated that MSCs also inhibit CD8
+
 T cell prolifera-
tion [127,156,157]. However, there are inconsistencies with 
regard to data on the effect of MSCs on CD8
+
 T cell cytotox-
icity [127,157], which may be explained in part by an effect 
of MSCs on cell number, possibly through an increase in cell 
death. Importantly, it seems that MSCs are not targets for 
destruction by CD8
+
 T cells [127]. 
 The other major component of the adaptive immune re-
sponse is humoral or antibody mediated immunity imple-
mented by B cells. Antibody mediated events have been as-
sociated with both acute and chronic rejection [107]. The 
effects of MSCs on B cell proliferation and function have 
been reported in vitro, with a small number of studies carried 
out using in vivo models. Data from the in vitro experiments 
involving co-culture of MSCs with purified populations of B 
cells under various stimulatory conditions, primarily demon-
strate an inhibitory effect of MSCs on B cell proliferation, 
differentiation, Immunoglobulin (Ig) production and chemo-
taxis [158-164]. So far the mechanisms responsible for MSC 
modulation of B cell functions have been identified as alter-
natively cleaved CCL2 [162] or the combined effects of IFN-
?, cell contact and PD1/PDL1 interaction [163]. In vivo mod-
els of pathogenic antibody production have demonstrated the 
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capacity of MSCs to inhibit Ig production (including both T 
cell dependent and independent antibody responses) in vivo 
[158,161,162]. In contrast, data from others groups focusing 
on mouse models of SLE did not support these findings; with 
evidence of MSC failure to suppress auto-antibody produc-
tion or increased auto-antibody titre and disease activity 
[163,165]. The discrepancy between these results may be 
due to differences in the systems examined (pathogenic ver-
sus autoimmune antibody production) or indeed the MSC 
populations used. Overall, the data highlight the capacity for 
MSC to modulate plasma cell function but also to stimulate 
these cells in specific circumstances and therefore empha-
sises the need for additional research using a number of dif-
ferent in vivo models in conjunction with a defined popula-
tion of MSCs to provide consistency. 
Influence of the Combined Effects of MSC Reparative 
and Immune Suppressive Capacities 
 As discussed above, organ transplantation is hampered 
not only by allogeneic rejection mechanisms but also ische-
mia/reperfusion or tissue injury associated with surgery. 
While current immunosuppressive regimens are targeted 
against the allogeneic rejection pathways; no specific meas-
ures are taken to combat the tissue injury common to organ 
transplantation. The immunosuppressive capabilities of 
MSCs combined with their inherent reparative functions, 
provides a possible therapeutic strategy to prevent graft re-
jection and enhance tissue repair. However, it seems likely 
that a combination therapy consisting of a brief period of 
immunosuppression followed by MSCs may facilitate a better 
outcome than MSCs or conventional immunosuppression alone. 
 Clearly the best studied clinical application of MSC ther-
apy is in hematopoietic stem cell (HSC) transplantation, ei-
ther for the enhancement of hematopoietic engraftment or for 
the treatment/prevention of GvHD. The capacity for MSCs 
to provide support for haematopoiesis combined with the 
inherent aptitude to encourage repair through secretion of 
trophic factors likely contributes to the increased levels and 
speed of engraftment seen in patients treated with MSCs 
[166,167]. As discussed above, one of the most interesting 
properties of MSCs is their capacity to modulate the immune 
response and data from clinical trials demonstrate a protec-
tive effect mediated by MSCs in patients with steroid resis-
tant acute GvHD [74]. These published findings provide a 
platform for the use of MSCs in other clinical indications 
particularly that of organ transplantation. Trials utilising 
MSCs in solid organ transplantation have recently been initi-
ated and over 100 trials using both the immune modulatory 
and or reparative effects of MSCs. The results from these 
trials will provide important insight into the applicability to 
MSCs in transplantation. 
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